The history behind the use of antipsychotic medications in persons with intellectual disability: Part II

Mental Health Aspects of Developmental Disabilities

Volumn 9, Issue 3, 2006, Pages 93-101

  Levitas, Andrew S ^a,c   Hurley, Anne DesNoyers ^b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UMDNJ School of Osteopathic Medicine   (United States)

Author keywords

Antipsychotic medication; Developmental disabilities; Intellectual disability (use in); Mental retardation; Psychiatric disorder; Tardive dyskinesia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE SUCCINATE; MESORIDAZINE BESYLATE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

COMORBIDITY; DRUG MISUSE; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HIGH RISK PATIENT; HISTORY; HUMAN; INTELLECTUAL IMPAIRMENT; MENTAL DEFICIENCY; MENTAL PATIENT; NEUROTRANSMITTER RELEASE; PSYCHOSIS; QUALITY OF LIFE; REVIEW; TARDIVE DYSKINESIA;

EID: 33748492106     PISSN: 10573291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity. Concensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
2. Abboud L. Johnson & Johnson's Risperdal raises tumor issue. Wall Street Journal June 17, 2005: A3.
3. Anderson LT, Campbell M, Grega DM, et al. Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry 1984;141:1195-1202.
4. Anderson LT, Campbell M, Adams P, et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989;19:227-239.
5. Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: Customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003;42:1443-1450.
6. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 2004;161:414-425.
7. Findling RL, Aman MG, Eerdekens M, et al. Long-term, open-label study of risperidone in children with severe disruptive behavior and below-average IQ. Am J Psychiatry 2004;161:677-684.
8. Glick ID, Murray SR, Vasudevan P, et al. Treatment with atypical antipsychotics: New indications and new populations. J Psychiatr Res 2001;35:187-191.
9. Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001;11:S397-S403.
10. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001;158:360-369.
11. Leonard H, Hoheneck D. Metabolic side effects of the atypical antipsychotic olanzapine in an inpatient population of adults with developmental disabilities. Ment Health Aspects Dev Disabil 2006;9:18-22.
12. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-efects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
13. Levitas A. Reader response to Zarcone et al., "Effects of risperidone on aberrant behavior in persons with developmental disabilities: I. A double-blind crossover study using multiple measures." Am J Ment Retard 2003;10:212-214.
14. Levitas A, Hurley A. The history behind the use of antipsychotic medications in persons with intellectual disability. Ment Health Aspects Dev Disabil 2006;9:26-32.
15. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005;162:1142-1148.
16. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610.
17. Psychiatry Drug Alerts 2005;19:49.
18. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. NEJM 2002;347:314-321.
19. Sandier L. Risperidone in children with autism and serious behavioral problems (letter). NEJM 2002;347:1890.
20. Silka VR, Levitas A, Hurley A. The recent alert on cardiac effects of psychotropic medications. Ment Health Aspects Dev Disabil 2001;4:125-128.
21. Stevens JR, Kymissis PI, Baker AJ. Elevated prolactin levels in male youths treated with risperidone and quetiapine. J Child Adolesc Psychopharmacol 2005;15:893-900.
22. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-622.
23. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667.
24. Zarcone JR, Hellings JA, Crandall K, et al. Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Ment Retard 2001;106:525-538.